MedTrace Logo

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

NCT00210392 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-03-30

No results posted yet for this study

Summary

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen

Conditions

  • Lymphoma, Mucosa-Associated Lymphoid Tissue

Interventions

DRUG

Bortezomib (drug)

Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Franco Cavalli · International Extranodal Lymphoma Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210392 on ClinicalTrials.gov